These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17418834)

  • 1. Serum human chorionic gonadotropin level after ovulation triggering is influenced by the patient's body mass index and the number of larger follicles.
    Detti L; Mitwally MF; Rode A; Yelian FD; Kruger M; Diamond MP; Puscheck EE
    Fertil Steril; 2007 Jul; 88(1):152-5. PubMed ID: 17418834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial.
    Serafini P; Yadid I; Motta EL; Alegretti JR; Fioravanti J; Coslovsky M
    Fertil Steril; 2006 Oct; 86(4):830-8. PubMed ID: 16963040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.
    Filicori M; Cognigni GE; Gamberini E; Parmegiani L; Troilo E; Roset B
    Fertil Steril; 2005 Aug; 84(2):394-401. PubMed ID: 16084880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation.
    Orvieto R; Zagatsky I; Yulzari-Roll V; La Marca A; Fisch B
    Gynecol Endocrinol; 2006 Aug; 22(8):437-40. PubMed ID: 17012105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women with ovulatory dysfunction undergoing ovarian stimulation with clomiphene citrate for intrauterine insemination may benefit from administration of human chorionic gonadotropin.
    Vlahos NF; Coker L; Lawler C; Zhao Y; Bankowski B; Wallach EE
    Fertil Steril; 2005 May; 83(5):1510-6. PubMed ID: 15866592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between serum human chorionic gonadotrophin levels and body mass index in women undergoing in vitro fertilisation cycles.
    Stefanis P; Das S; Barsoum-Derias E; Kingsland C; Lewis-Jones I; Gazvani R
    Eur J Obstet Gynecol Reprod Biol; 2007 Jun; 132(2):204-8. PubMed ID: 17011694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
    Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
    Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Ross R; Morris S
    Fertil Steril; 2005 Jul; 84(1):93-8. PubMed ID: 16009163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization.
    Kovacs P; Kovats T; Bernard A; Zadori J; Szmatona G; Kaali SG
    Fertil Steril; 2008 Dec; 90(6):2133-7. PubMed ID: 18177866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo maturation of oocytes by extending the interval between human chorionic gonadotropin administration and oocyte retrieval.
    Raziel A; Schachter M; Strassburger D; Kasterstein E; Ron-El R; Friedler S
    Fertil Steril; 2006 Sep; 86(3):583-7. PubMed ID: 16828475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles.
    Griesinger G; Kolibianakis EM; Papanikolaou EG; Diedrich K; Van Steirteghem A; Devroey P; Ejdrup Bredkjaer H; Humaidan P
    Fertil Steril; 2007 Sep; 88(3):616-21. PubMed ID: 17451691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
    Papaleo E; Unfer V; Baillargeon JP; Fusi F; Occhi F; De Santis L
    Fertil Steril; 2009 May; 91(5):1750-4. PubMed ID: 18462730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal induction of ovulation stimulates atresia of antral follicles in a vespertilionid bat, Scotophilus heathi.
    Chanda D; Abhilasha ; Krishna A
    Zoology (Jena); 2006; 109(3):208-16. PubMed ID: 16814533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum androgen levels in patients undergoing controlled ovarian hyperstimulation for in vitro fertilization cycles.
    Orvieto R; Yulzari-Roll V; La Marca A; Ashkenazi J; Fisch B
    Gynecol Endocrinol; 2005 Oct; 21(4):218-22. PubMed ID: 16316843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.